Exelixis Inc (EXEL) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Exelixis Inc, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track EXEL live on Mooboard →

Later6

  • Dec 15, 2026
    Exelixis Inc(EXEL)Phase 2/3 readout
    XL092 · Phase 3 · Non-Clear Cell Renal Cell Carcinoma
    NCT05678673: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Primary completion 2026-12-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 29, 2028
    Exelixis Inc(EXEL)Phase 2/3 readout
    Zanzalintinib · Phase 2 · Meningioma
    NCT07428616: A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma. Primary completion 2028-02-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 2028
    Exelixis Inc(EXEL)Phase 2/3 readout
    Zanzalintinib · Phase 2 / Phase 3 · Head and Neck Squamous Cell Carcinoma
    NCT06082167: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Primary completion 2028-08 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2029
    Exelixis Inc(EXEL)Phase 2/3 readout
    Zanzalintinib · Phase 2 / Phase 3 · Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
    NCT06943755: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors. Primary completion 2029-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 5, 2030
    Exelixis Inc(EXEL)Phase 2/3 readout
    Zanzalintinib · Phase 3 · Colorectal Cancer
    NCT07750158: Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease. Primary completion 2030-04-05 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2030
    Exelixis Inc(EXEL)Phase 2/3 readout
    Cabozantinib · Phase 3 · Cancer; Renal Cell Carcinoma (RCC)
    NCT07620574: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study. Primary completion 2030-05-31 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How Exelixis Inc has moved — past-year price reactions

How binary is EXEL? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
1
±10% days
36.3%
annualized vol
250
trading days
Largest single-day moves
  • -12%2025-10-20no matched headline
  • +9.6%2026-05-06no matched headline
  • -7.9%2026-08-06no matched headline
  • -6.9%2026-03-02no matched headline
  • +6.5%2025-11-05no matched headline
  • +6.3%2026-06-03no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Exelixis Inc — active clinical pipeline

Exelixis Inc's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

8 assets20 programsPh1 8Ph2 1Ph3 10· 1 post-marketing (Ph4)
AreasOncologyOther
CabozantinibOncology
Phase 1
Urothelial Carcinoma
Phase 3
CancerDifferentiated Thyroid CancerHepatocellular CarcinomaMetastatic Prostate CancerRenal Cell Carcinoma
ZanzalintinibOncology
Phase 1
Hepatic ImpairmentRenal Cell Carcinoma (RCC)
Phase 2
Meningioma
Phase 3
Colorectal CancerHead and Neck Squamous Cell CarcinomaPancreatic Neuroendocrine Tumor (pNET)
XL092Oncology
Phase 1
Neoplasm Malignant
Phase 3
Colorectal CancerNon-Clear Cell Renal Cell Carcinoma
XB010Oncology
Phase 1
Locally Advanced or Metastatic Solid Tumors
XB371Oncology
Phase 1
Solid Tumors
XB628Oncology
Phase 1
Solid Tumor
XL309Oncology
Phase 1
Advanced Solid Tumor

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.